Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6075)	4/2/2002 5:53:53 PM
From: Tomato	Respond to of 52153

Peter, Thanks for the thoughtful reply. I keep thinking about Peter Lynch's first book (I think it was his first one) where he uses the approval of Tagamet as an example of how to invest. I don't have the book here but I recall he had a chart of Smith Kline (?) which I think went up several times in a few years after the drug's approval. I think the message was that you could wait for the risk to be out of the stock and still make a lot of money. But I guess if it were that easy to figure out everyone would just buy a stock after a blockbuster drug is approved. <g>

To: Biomaven who wrote (6075)	4/2/2002 5:54:50 PM
From: Tomato	Respond to of 52153

Peter, Thanks for the thoughtful reply. I keep thinking about Peter Lynch's first book (I think it was his first one) where he uses the approval of Tagamet as an example of how to invest. I don't have the book here but I recall he had a chart of Smith Kline (?) which I think went up several times in a few years after the drug's approval. I think the message was that you could wait for the risk to be out of the stock and still make a lot of money. But I guess if it were that easy to figure out everyone would just buy a stock after a blockbuster drug is approved. <g> Wayne

To: Biomaven who wrote (6075)	4/3/2002 12:55:36 PM
From: tuck	Read Replies (1) \| Respond to of 52153

Peter, Or anyone. On similar lines, but somewhat OT in that it doesn't much relate to valuation . . . I was wondering if another good time to buy is when a stock approaches lows, announces a shareholder rights plan, and goes down a bit more. Perhaps the second downdraft is a final wave of selling from nervous nellies who figure there must be something bad happening for such a measure to be taken. Today's case is CRGN, which I have again bought for a swing trade as it approaches lows after just such an announcement. If I didn't have enough threads to look after already, I'd be tempted to create a "Shareholder Rights Hell" portfolio. Anyone want the job? Or, at least, has anyone noticed any patterns surrounding the above circumstances? Cheers, Tuck